MCM Vaccines

MCM Vaccine is a specialized joint venture between Sanofi and MSD, established to co-develop and commercialize a single hexavalent pediatric vaccine. The company leverages over 35 years of collaboration between its parent organizations, combining their proven antigens and extensive experience in vaccine development and manufacturing. Its sole product is a marketed vaccine indicated for primary and booster immunization, positioning the entity as a commercial-stage, single-asset company operating within a well-defined global partnership structure.

Combination of proven antigens from Sanofi and MSD into a stable, immunogenic hexavalent pediatric vaccine formulation.

The pediatric hexavalent vaccine market is competitive, dominated by large players like GSK, Sanofi, and MSD. MCM's product competes directly with other hexavalent vaccines on factors such as antigen composition, immunogenicity profile, safety, tolerability, and price in government-led tender processes.